keyword
MENU ▼
Read by QxMD icon Read
search

HPV vaccines safety

keyword
https://www.readbyqxmd.com/read/28087890/overview-of-the-benefits-and-potential-issues-of-the-nonavalent-hpv-vaccine
#1
REVIEW
Luciano Mariani, Mario Preti, Paolo Cristoforoni, Carlo M Stigliano, Antonio Perino
HPV-related diseases affect anogenital and oropharyngeal regions, heavily affecting the psychosexual dimension of both male and female individuals. HPV vaccination programs based on a bivalent or quadrivalent vaccine have opened broad perspectives for primary prevention. A nonavalent HPV vaccine (9vHPV), covering nine genotypes (HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, and HPV58), might provide further improvement in terms of direct protection. In the present report, efficacy and safety data from 9vHPV vaccine development programs are examined...
December 7, 2016: International Journal of Gynaecology and Obstetrics
https://www.readbyqxmd.com/read/28073618/characteristics-of-adolescents-lacking-provider-recommended-human-papillomavirus-vaccination
#2
Melinda Krakow, Anna Beavis, Olivia Cosides, Anne F Rositch
PURPOSE: To characterize subgroups of teens in the United States for whom provider recommendation is less likely to impact human papillomavirus (HPV) vaccine initiation. METHODS: We analyzed provider-verified vaccination data from the Centers for Disease Control and Prevention's 2014 National Immunization Survey-Teen. Poisson regression models identified characteristics associated with the lack of HPV vaccine initiation among teens who received a provider recommendation (n = 12,742)...
January 7, 2017: Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine
https://www.readbyqxmd.com/read/28073220/what-do-we-know-about-the-safety-of-the-hpv-vaccines
#3
Peter C Gøtzsche
No abstract text is available yet for this article.
January 2017: Tidsskrift for Den Norske Lægeforening: Tidsskrift for Praktisk Medicin, Ny Række
https://www.readbyqxmd.com/read/28053505/spotlight-on-the-9-valent-hpv-vaccine
#4
REVIEW
Pier Luigi Lopalco
Starting in 2006, vaccination against human papillomavirus (HPV) has been progressively implemented in most developed countries. Two vaccines have been successfully used, a bivalent vaccine targeting HPV-related cancers (bHPV) and a quadrivalent vaccine (qHPV) targeting both HPV-related cancers and genital warts. Between December 2014 and June 2015, a new nonavalent HPV vaccine (9vHPV) was granted marketing authorization in the USA and Europe. The 9vHPV was developed from the qHPV and includes five additional HPV types that should increase the level of protection toward HPV-related cancers...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28042137/immunogenicity-and-safety-of-human-papillomavirus-hpv-vaccination-in-asian-populations-from-six-countries-a-meta-analysis
#5
Didik Setiawan, Jos Luttjeboer, Koen B Pouwels, Jan C Wilschut, Maarten J Postma
Cervical cancer is a serious public-health problem in Asian countries. Since human papillomavirus (HPV) infection is the main risk factor for cervical cancer, HPV vaccination is considered a promising strategy to prevent cervical cancer. However, comprehensive immunogenicity and safety information for Asian populations is lacking. We searched four electronic databases including PubMed, EMBASE, Cochrane Library, and clinicaltrials.gov. We reviewed selected manuscripts and extracted the pooled relative risk (RR) from immunogenicity and safety information on HPV vaccination among women in Asian countries...
January 1, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28003597/safety-and-immunogenicity-study-of-a-9-valent-human-papillomavirus-vaccine-administered-to-9-to-15-year-old-japanese-girls
#6
Satoshi Iwata, Shinya Murata, Shi Rong Han, Akira Wakana, Miyuki Sawata, Yoshiyuki Tanaka
A 9-valent human papillomavirus (HPV 6/11/16/18/31/33/45/52/58) virus-like particle (VLP) vaccine (9vHPV) has been proven highly efficacious in preventing anogenital disease related with vaccine HPV types in a pivotal Phase III study in women aged 16 to 26 years. We report here the results of an open-label phase III study conducted to bridge the findings in women age 16 to 26 years to Japanese girls aged 9 to 15 years. All subjects (n = 100) received a 3-dose regimen of 9vHPV vaccine at day 1, month 2 and month 6...
December 22, 2016: Japanese Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27998015/efficacy-immunogenicity-and-safety-of-the-hpv-16-18-as04-adjuvanted-vaccine-in-chinese-women-aged-18-25%C3%A2-years-event-triggered-analysis-of-a-randomized-controlled-trial
#7
Feng-Cai Zhu, Shang-Ying Hu, Ying Hong, Yue-Mei Hu, Xun Zhang, Yi-Ju Zhang, Qin-Jing Pan, Wen-Hua Zhang, Fang-Hui Zhao, Cheng-Fu Zhang, Xiaoping Yang, Jia-Xi Yu, Jiahong Zhu, Yejiang Zhu, Feng Chen, Qian Zhang, Hong Wang, Changrong Wang, Jun Bi, Shiyin Xue, Lingling Shen, Yan-Shu Zhang, Yunkun He, Haiwen Tang, Naveen Karkada, Pemmaraju Suryakiran, Dan Bi, Frank Struyf
We previously reported the results of a phase II/III, double-blind, randomized controlled study in Chinese women (NCT00779766) showing a 94.2% (95% confidence interval: 62.7-99.9) HPV-16/18 AS04-adjuvanted vaccine efficacy (VE) against cervical intraepithelial neoplasia grade 1 or higher (CIN1+) and/or 6-month (M) persistent infection (PI) with a mean follow-up of <2 years, and immunogenicity until 7 months post-dose 1. Here, we report efficacy and safety results from an event-triggered analysis with ~3 years longer follow-up, and immunogenicity until M24...
December 20, 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27940751/achieving-high-adolescent-hpv-vaccination-coverage
#8
Anna-Lisa M Farmar, Kathryn Love-Osborne, Katherine Chichester, Kristin Breslin, Kristi Bronkan, Simon J Hambidge
BACKGROUND AND OBJECTIVE: Despite national recommendations for adolescent human papillomavirus (HPV) vaccination, rates have lagged behind those of other adolescent vaccines. We implemented interventions and examined rates of vaccination coverage in a large, urban, safety net health care system to understand whether our tactics for achieving high rates of adolescent vaccination were successful. METHODS: Denver Health is an integrated urban safety net health system serving >17 000 adolescents annually...
November 2016: Pediatrics
https://www.readbyqxmd.com/read/27934795/current-global-status-impact-of-human-papillomavirus-vaccination-implications-for-india
#9
REVIEW
Rengaswamy Sankaranarayanan, Neerja Bhatla, Partha Basu
This review addresses the effectiveness and safety of human papillomavirus (HPV) vaccines, the current status of its introduction in the National Immunization Programmes (NIPs) and its relevance to India, which contributes a fifth of the global burden of cervical cancer. The vast literature on efficacy, acceptability and safety of HPV vaccination and its impact after population level introduction was reviewed and discussed. The efficacy of HPV vaccines in preventing high-grade precancerous lesions caused by vaccine-targeted HPV infections was 90 per cent or higher in HPV naοve women in randomized clinical trials...
August 2016: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/27912928/translating-self-persuasion-into-an-adolescent-hpv-vaccine-promotion-intervention-for-parents-attending-safety-net-clinics
#10
Austin S Baldwin, Deanna C Denman, Margarita Sala, Emily G Marks, L Aubree Shay, Sobha Fuller, Donna Persaud, Simon Craddock Lee, Celette Sugg Skinner, Deborah J Wiebe, Jasmin A Tiro
OBJECTIVE: Self-persuasion is an effective behavior change strategy, but has not been translated for low-income, less educated, uninsured populations attending safety-net clinics or to promote human papillomavirus (HPV) vaccination. We developed a tablet-based application (in English and Spanish) to elicit parental self-persuasion for adolescent HPV vaccination and evaluated its feasibility in a safety-net population. METHODS: Parents (N=45) of age-eligible adolescents used the self-persuasion application...
November 20, 2016: Patient Education and Counseling
https://www.readbyqxmd.com/read/27910798/a-qualitative-study-of-women-who-experience-side-effects-from-human-papillomavirus-vaccination
#11
Tina Sørensen, Pernille Tanggaard Andersen
INTRODUCTION: In Denmark, vaccination against human papillomavirus (HPV) is offered to girls and women to prevent cervical cancer. Unfortunately, reporting of possible side effects from vaccination has increased in recent years. Therefore, the present study examine women's experiences of side effects from the HPV vaccine. METHODS: In-depth qualitative interviews were conducted with eight HPV-vaccinated Danish women, aged 25-44 years, who experienced side effects from the vaccine...
December 2016: Danish Medical Journal
https://www.readbyqxmd.com/read/27895921/literature-review-of-vaccine-related-adverse-events-reported-from-hpv-vaccination-in-randomized-controlled-trials
#12
Mohamed Macki, Ali A Dabaja
BACKGROUND: The human papilloma virus (HPV) infections were addressed with two FDA-approved HPV vaccines: quadrivalent and bivalent vaccine. The objective of this manuscript is to determine the safety of the HPV vaccine. RESULTS: A search of PubMed articles for "human papillomavirus vaccine" was used to identify all-type HPV clinical studies prior to October 2014. A refined search of clinical trials, multicenter studies, and randomized studies were screened for only randomized controlled trials comparing HPV vaccine to controls (saline placebo or aluminum derivatives)...
2016: Basic and Clinical Andrology
https://www.readbyqxmd.com/read/27864489/protecting-women-against-human-papillomavirus-benefits-barriers-and-evidence-based-strategies-to-increase-vaccine-uptake
#13
Tamera Coyne-Beasley, Bridget E Hochwalt
Human papillomavirus (HPV) infection significantly impacts women, as it can cause cancers and precancers of the cervix, vulva, vagina, oropharynx, and anus. However, many of these cancers can be prevented by HPV vaccination. Despite evidence of vaccine effectiveness and safety, vaccination rates remain low. Evidence-based strategies should be utilized to reduce barriers and increase vaccination rates.
November 2016: North Carolina Medical Journal
https://www.readbyqxmd.com/read/27858522/hpv-vaccine-related-knowledge-beliefs-acceptability-and-uptake-among-latinas-who-prefer-english-and-those-who-prefer-spanish
#14
Kimlin Tam Ashing, Noé Rubén Chávez, Mayra Serrano
Latinas compose almost 10% of the U.S. population and suffer the highest incidence of and one of the highest mortality rates from cervical cancer. Human papillomavirus (HPV) vaccination can prevent most HPV infections that cause more than 90% of cervical cancer. Unfortunately, limited knowledge and low rates of HPV vaccination persist among Latinas. The current study compared awareness, knowledge, beliefs, acceptability, uptake, and 3-dose series completion of HPV vaccination between Latinas who prefer English (EPL) and those who prefer Spanish (SPL), ages 18-62, living in Southern California...
December 2016: Journal of Health Communication
https://www.readbyqxmd.com/read/27856770/update-from-the-advisory-committee-on-immunization-practices
#15
Jennifer E Schuster, Sean O'Leary, David W Kimberlin
The Advisory Committee on Immunization Practices (ACIP) consists of medical and public health experts who develop recommendations on vaccine use in the United States. The ACIP meets 3 times per year, and members and Centers for Disease Control (CDC) staff present findings and discuss vaccine research, vaccine effectiveness (VE) and safety, clinical trial results, and labeling/package insert information. Outbreaks of vaccine-preventable diseases and vaccine shortages are also discussed. Nonvoting representatives from the American Academy of Pediatrics and the Pediatric Infectious Diseases Society are present...
December 2016: Journal of the Pediatric Infectious Diseases Society
https://www.readbyqxmd.com/read/27777126/design-of-a-long-term-follow-up-effectiveness-immunogenicity-and-safety-study-of-women-who-received-the-9-valent-human-papillomavirus-vaccine
#16
Alain Luxembourg, Susanne K Kjaer, Mari Nygard, Misoo C Ellison, Thomas Group, J Brooke Marshall, David Radley, Alfred Saah
The 9-valent human papillomavirus (HPV) (9vHPV) vaccine targets four HPV types (6/11/16/18) also covered by the quadrivalent HPV (qHPV) vaccine and five additional types (31/33/45/52/58). Vaccine efficacy to prevent HPV infection and disease was established in a Phase III clinical study in women 16-26years of age. A long-term follow-up (LTFU) study has been initiated as an extension of the Phase III clinical study to assess effectiveness of the 9vHPV vaccine up to at least 14years after the start of vaccination...
January 2017: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/27737666/experiences-and-lessons-learned-from-29-hpv-vaccination-programs-implemented-in-19-low-and-middle-income-countries-2009-2014
#17
Joël Ladner, Marie-Hélène Besson, Etienne Audureau, Mariana Rodrigues, Joseph Saba
BACKGROUND: Cervical cancer is the greatest cause of age-weighted years of life lost in the developing world. Human papillomavirus (HPV) infection is associated with a high proportion of cervical cancers, and HPV vaccination may help to reduce the incidence of cancer. The aim of the study was to identify barriers, obstacles, and strategies and to analyze key concerns and lessons learned with respect to the implementation of HPV vaccination program in low- and middle-income countries. METHODS: The Gardasil Access Program (GAP) is a donation program established to enable organizations and institutions in eligible low-resource countries to gain operational experience designing and implementing HPV vaccination programs...
October 13, 2016: BMC Health Services Research
https://www.readbyqxmd.com/read/27718061/society-of-behavioral-medicine-supports-increasing-hpv-vaccination-uptake-an-urgent-opportunity-for-cancer-prevention
#18
Caryn E Peterson, J Andrew Dykens, Noel T Brewer, Joanna Buscemi, Karriem Watson, DeLawnia Comer-Hagans, Zo Ramamonjiarivelo, Marian Fitzgibbon
Human papillomavirus (HPV) vaccine coverage remains low in the USA. The Society for Behavioral Medicine (SBM) supports the goals outlined by Healthy People 2020, the President's Cancer Panel, and the National Vaccine Advisory Committee to increase vaccination coverage among both males and females. SBM makes the following recommendations in support of efforts to reduce structural and other barriers to HPV vaccination services in order to increase rates of series completion. We encourage legislators and other policymakers to improve administration authority, insurance coverage, and reimbursement rates to healthcare providers who make the HPV vaccine available to adolescents; provide instrumental support to fund the development of school curricula on HPV vaccination; and increase public awareness that HPV vaccination can prevent cancer...
December 2016: Translational Behavioral Medicine
https://www.readbyqxmd.com/read/27687213/facilitators-and-barriers-to-the-use-of-standing-orders-for-vaccination-in-obstetrics-and-gynecology-settings
#19
Juliana G Barnard, Amanda F Dempsey, Sarah E Brewer, Jennifer Pyrzanowski, Sara E Mazzoni, Sean T O'Leary
BACKGROUND: Many young and middle-aged women receive their primary health care from their obstetrician-gynecologists. A recent change to vaccination recommendations during pregnancy has forced the integration of new clinical processes at obstetrician-gynecology practices. Evidence-based best practices for vaccination delivery include the establishment of vaccination standing orders. OBJECTIVES: As part of an intervention to increase adoption of evidence-based vaccination strategies for women in safety-net and private obstetrician-gynecology settings, we conducted a qualitative study to identify the facilitators and barriers experienced by obstetrician-gynecology sites when establishing vaccination standing orders...
January 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/27682966/human-papillomavirus-infection-and-cervical-lesions-in-rheumatic-diseases-a-systematic-review
#20
A Raposo, C Tani, J Costa, M Mosca
An association between immune-mediated diseases and cervical pre-malignant and malignant lesions is described, having the human papillomavirus (HPV) infection a causal role. Related studies have been generally focused on systemic lupus erythematosus (SLE) patients, but relatively to other diseases, such as rheumatoid arthritis (RA), Sjögren's syndrome (SS) and systemic sclerosis (SSc), data has not been systematically evaluated. We conducted a systematic review analysis of the literature in PubMed, including articles published until March of 2015, in patients with RA, SS, SLE and SSc, to evaluate the frequency of HPV infection, cervical dysplasia and cervical cancer, and associated factors, with particular interest on the role of glucocorticoids and immunosuppressive treatment...
July 2016: Acta Reumatológica Portuguesa
keyword
keyword
102610
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"